FDA To Review Under the Skin Weekly Autoinjector For Biogen/Eisai's Alzheimer's Drug Leqembi
REGENXBIO Partners With Nippon Shinyaku in $810M Deal for Hunter and Hurler Syndrome Therapies
Reported Earlier, Eisai And Biogen Announced FDA Acceptance Of LEQEMBI BLA For Weekly Subcutaneous Dosing To Treat Early Alzheimer's Disease
MediciNova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of MN-166 In ALS At The 35th International Symposium On ALS/MND
D. Boral Capital Initiates Coverage On MediciNova With Buy Rating, Announces Price Target of $9
MediciNova Analyst Ratings